David Narrow '12 is CEO of company launching surgery site marker
Sonavex Inc., a Baltimore-based medical device company spun out of John Hopkins, has received $4.5 million in venture capital funding to accelerate its launch later this year of a new implant to mark soft tissue sites after surgery.
David Narrow ’12, a biomedical engineering alumnus of the University of Rochester and co-founder of MonoMano Cycling, is Sonavex’s CEO.
The product, called EchoMark, is a highly echogenic, resorbable polymeric implant that can mark the site of a surgical procedure, such as a breast lumpectomy, so the site can be precisely relocated later with ultrasound if an additional procedure is needed. The implant is a “specially design form factor that provides intuitive, continuous changes in its two-dimensional ultrasound outline when imaged from different angles and positions,” the company says.
Narrow, who graduated from the University of Rochester “with highest distinction,” was part of the senior design team that created the MonoMano Trike, which enables stroke victims, veterans, and other people with disabilities to return to the sport of cycling and gain full steering, braking and gear-shifting control with only one hand.
He received his master’s in bioengineering innovation and design from John Hopkins in 2013 and became CEO of Sonavex the following year.
Read more here.